Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Reversible Doxorubicin-Induced Congestive Heart Failure

Reversible Doxorubicin-Induced Congestive Heart Failure Abstract Doxorubicin hydrochloride is a chemotherapeutic agent highly effective against a wide range of neoplasms. A prime limiting factor to the administration of this drug is cardiotoxicity, which frequently develops when the cumulative dose exceeds 500 mg/sq m. Late cardiomyopathy, which may develop up to a year after therapy has been discontinued, was thought to be rapidly progressive and unresponsive to standard cardiac therapy. An adult who received 475 mg/sq m of doxorubicin hydrochloride experienced a cardiotoxic reaction one year after the completion of therapy. The patient responded to standard cardiac therapy. Resolution of left ventricular dysfunction was verified by echocardiography and radionuclide angiocardiography. (Arch Intern Med 1982;142:1570-1571) References 1. Henderson IC, Fred E: Adriamycin cardiotoxicity. Am Heart J 1980;99:671-673.Crossref 2. Bristow MR, Billingham ME, Mason JE, et al: Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 1978;62:873-879. 3. Friedman MJ, Ewy GA, Jones SE: One year follow up of cardiac status after adriamycin therapy. Cancer Treat Rep 1979;63:1809-1816. 4. Gottlieb SL, Edminston A, Haywood LT: Late doxorubicin cardiotoxicity. Chest 1980;78:880-882.Crossref 5. Balcerzak SP, Christakis T, Lewis RP, et al: Systolic time intervals in monitoring adriamycin induced cardiotoxicity. Cancer Treat Rep 1978; 62:893-899. 6. Borer JS, Gottdiener JS, Mathisen DJ: Doxorubicin cardiotoxicity: Assessment of late left ventricular dysfunction by radionuclide cineangiography. Ann Intern Med 1981;94:430-435.Crossref 7. Bristow MR, Mason JE, Billingham ME, et al: Doxorubicin cardiomyopathy: Evaluation by phonocardiography, endomyocardial biopsy and cardiac catheterization. Ann Intern Med 1978;88:168-175.Crossref 8. Mason JW, Bristown MR, Billingham ME, et al: Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: Superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep 1978;62:857-864. 9. Von Hoff DD, Layard MM, Basa P, et al: Risk factors for doxorubicininduced congestive heart failure. Ann Intern Med 1979;91:710-717.Crossref 10. Bristow MR, Mason JW, Billingham ME, et al: Dose effect and structure: Function relationships in doxorubicin cardiomyopathy. Am Heart J 1981;102:709-718.Crossref 11. Lefark EA, Pitha J, Rosenhein S: Clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302-314.Crossref 12. Alexander JE, Daniak N, Berger HJ, et al: Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 1979;300:278-283.Crossref 13. Goorin AM, Burow KM, Goldman A, et al: Congestive heart failure due to adriamycin cardiotoxicity: Its natural history in children. Cancer 1981;47:2810-2816.Crossref 14. Koneke LL, Feibenbaum H, Chang S, et al: Abnormal mitral valve motion in patients with elevated left ventricular diastolic pressure. Circulation 1973;47:989.Crossref 15. Praga C, Beretta G, Bigo PL, et al: Adriamycin cardiotoxicity: A survey of 1,273 patients. Cancer Treat Rep 1979;63:827-834. 16. Weyman AE: Pulmonary valve echo motion in clinical practice. Am J Med 1977;62:843.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Internal Medicine American Medical Association

Reversible Doxorubicin-Induced Congestive Heart Failure

Loading next page...
 
/lp/american-medical-association/reversible-doxorubicin-induced-congestive-heart-failure-UG5Cx6Qm05
Publisher
American Medical Association
Copyright
Copyright © 1982 American Medical Association. All Rights Reserved.
ISSN
0003-9926
eISSN
1538-3679
DOI
10.1001/archinte.1982.00340210168032
Publisher site
See Article on Publisher Site

Abstract

Abstract Doxorubicin hydrochloride is a chemotherapeutic agent highly effective against a wide range of neoplasms. A prime limiting factor to the administration of this drug is cardiotoxicity, which frequently develops when the cumulative dose exceeds 500 mg/sq m. Late cardiomyopathy, which may develop up to a year after therapy has been discontinued, was thought to be rapidly progressive and unresponsive to standard cardiac therapy. An adult who received 475 mg/sq m of doxorubicin hydrochloride experienced a cardiotoxic reaction one year after the completion of therapy. The patient responded to standard cardiac therapy. Resolution of left ventricular dysfunction was verified by echocardiography and radionuclide angiocardiography. (Arch Intern Med 1982;142:1570-1571) References 1. Henderson IC, Fred E: Adriamycin cardiotoxicity. Am Heart J 1980;99:671-673.Crossref 2. Bristow MR, Billingham ME, Mason JE, et al: Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 1978;62:873-879. 3. Friedman MJ, Ewy GA, Jones SE: One year follow up of cardiac status after adriamycin therapy. Cancer Treat Rep 1979;63:1809-1816. 4. Gottlieb SL, Edminston A, Haywood LT: Late doxorubicin cardiotoxicity. Chest 1980;78:880-882.Crossref 5. Balcerzak SP, Christakis T, Lewis RP, et al: Systolic time intervals in monitoring adriamycin induced cardiotoxicity. Cancer Treat Rep 1978; 62:893-899. 6. Borer JS, Gottdiener JS, Mathisen DJ: Doxorubicin cardiotoxicity: Assessment of late left ventricular dysfunction by radionuclide cineangiography. Ann Intern Med 1981;94:430-435.Crossref 7. Bristow MR, Mason JE, Billingham ME, et al: Doxorubicin cardiomyopathy: Evaluation by phonocardiography, endomyocardial biopsy and cardiac catheterization. Ann Intern Med 1978;88:168-175.Crossref 8. Mason JW, Bristown MR, Billingham ME, et al: Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: Superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep 1978;62:857-864. 9. Von Hoff DD, Layard MM, Basa P, et al: Risk factors for doxorubicininduced congestive heart failure. Ann Intern Med 1979;91:710-717.Crossref 10. Bristow MR, Mason JW, Billingham ME, et al: Dose effect and structure: Function relationships in doxorubicin cardiomyopathy. Am Heart J 1981;102:709-718.Crossref 11. Lefark EA, Pitha J, Rosenhein S: Clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302-314.Crossref 12. Alexander JE, Daniak N, Berger HJ, et al: Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 1979;300:278-283.Crossref 13. Goorin AM, Burow KM, Goldman A, et al: Congestive heart failure due to adriamycin cardiotoxicity: Its natural history in children. Cancer 1981;47:2810-2816.Crossref 14. Koneke LL, Feibenbaum H, Chang S, et al: Abnormal mitral valve motion in patients with elevated left ventricular diastolic pressure. Circulation 1973;47:989.Crossref 15. Praga C, Beretta G, Bigo PL, et al: Adriamycin cardiotoxicity: A survey of 1,273 patients. Cancer Treat Rep 1979;63:827-834. 16. Weyman AE: Pulmonary valve echo motion in clinical practice. Am J Med 1977;62:843.Crossref

Journal

Archives of Internal MedicineAmerican Medical Association

Published: Aug 1, 1982

References